Organic anion transporter 5 (Oat5) renal expression and urinary excretion in rats treated with cisplatin: a potential biomarker of cisplatin-induced nephrotoxicity

• Published in: Archives of toxicology 2013-11, Vol.87 (11), p.1953-1962
• Main Authors: Bulacio, Romina Paula, Torres, Adriana Mónica
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - toxicity; Biomarkers; Biomarkers - urine; Biomedical and Life Sciences; Biomedicine; Blotting, Western; Chemotherapy; Cisplatin - toxicity; Creatinine - blood; Dicarboxylic Acid Transporters - biosynthesis; Dicarboxylic Acid Transporters - urine; Electrophoresis; Environmental Health; Gene expression; Glycosuria - chemically induced; Immunohistochemistry; Kidney - metabolism; Kidney - pathology; Kidney Cortex - pathology; Kidney diseases; Kidney Diseases - chemically induced; Kidney Diseases - pathology; Kidney Diseases - urine; Kidney Function Tests; Kidney Tubules - pathology; Male; Membranes - metabolism; Membranes - pathology; Occupational Medicine/Industrial Medicine; Organ Toxicity and Mechanisms; Pharmacology/Toxicology; Proteinuria - chemically induced; Rats; Rodents; Side effects; Toxicity; Urea - blood
• ISSN: 0340-5761; 1432-0738
• DOI: 10.1007/s00204-013-1062-0

Cisplatin is one of the most potent chemotherapeutic antitumor drugs used in the treatment of a wide range of solid tumors. Its primary dose-limiting side effect is nephrotoxicity. The organic anion transporter 5 (Oat5) is exclusively localized in the kidney. Oat5 urinary excretion was recently proposed as a potential early biomarker of acute kidney injury (AKI). The aim of this study was to evaluate Oat5 renal expression and its urinary excretion in rats exposed to different doses of cisplatin, in comparison with traditional markers of renal injury, like renal histology, creatinine and urea plasma levels, creatinine clearance, protein and glucose urinary levels and urinary alkaline phosphatase (AP) activity. Male Wistar rats were treated with a single injection of cisplatin at different doses of 1, 2, 5 and 10 mg/kg b.w., i.p. (Cis1, Cis2, Cis5 and Cis10, n  = 4, respectively) and experiments were carried out 48 h after cisplatin administration. The renal expression of Oat5 was evaluated by immunohistochemistry and Western blotting. Oat5 abundance, AP activity, creatinine, glucose and proteins were assayed in urine. Creatinine clearance and creatinine and urea plasma levels were also evaluated. In this experimental model, plasma urea and creatinine levels, creatinine clearance, AP urinary activity and protein and glucose urinary levels were significantly modified only at the highest cisplatin dose of 10 mg/kg b.w., i.p., as compared to control rats. In contrast, Oat5 urinary abundance was increased in a dose-related manner after the administration of cisplatin. Oat5 urinary abundance was elevated at a dose as low as 1 mg/kg b.w., i.p., implying renal perturbation, when no modifications of traditional markers of renal injury are yet observed. Oat5 renal expression was decreased in a dose-related manner, both in homogenates and apical membranes from cisplatin-treated kidneys. The increase in urinary Oat5 excretion might explain the decrease in the amount of Oat5 molecules in the renal tubule cells. Hence, the preclinical animal results showed in this work propose that Oat5 urinary excretion might potentially serve as a non-invasive early biomarker of cisplatin-induced AKI.